TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma.
chemoembolization
hepatocellular carcinoma
lipiodol
prognostic factors
transaminases
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
17 Oct 2021
17 Oct 2021
Historique:
received:
07
09
2021
revised:
12
10
2021
accepted:
13
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
The aim of the present study was to correlate laboratory data and postprocedural parameters after conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) with the radiological response. The study consisted of a retrospective analysis of prospectively collected data from 70 consecutive patients who underwent cTACE. Laboratory parameters were assessed daily after cTACE and compared to pretreatment values. Post-treatment radiological response was assessed using mRECIST at one month from cTACE, and factors associated with treatment response (complete and objective response) were assessed by logistic regression analysis. The optimal cutoff points in predicting the complete response of target lesions were a 52% ALT and a 46% AST increase after cTACE compared to the pre-treatment values. Using multivariate analyses, >46% AST and >52% ALT increases with respect to the pre-treatment value were significantly correlated with the objective response (
Identifiants
pubmed: 34683182
pii: jpm11101041
doi: 10.3390/jpm11101041
pmc: PMC8539564
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Gastroenterol. 2003;38(3):207-15
pubmed: 12673442
Med Clin (Barc). 2010 May 8;134(13):569-76
pubmed: 20036398
J Hepatol. 2019 May;70(5):893-903
pubmed: 30660709
Ann Oncol. 2013 Oct;24(10):2565-2570
pubmed: 23857958
Semin Liver Dis. 2010 Feb;30(1):61-74
pubmed: 20175034
Br J Cancer. 2003 Oct 20;89(8):1423-7
pubmed: 14562011
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Am J Gastroenterol. 2016 Jan;111(1):70-7
pubmed: 26729544
Cancer Treat Rev. 2019 Jan;72:28-36
pubmed: 30447470
World J Hepatol. 2015 Aug 8;7(16):2009-19
pubmed: 26261690
Hepatology. 2000 Apr;31(4):840-5
pubmed: 10733537
Hepatol Res. 2007 Sep;37 Suppl 2:S230-7
pubmed: 17877488
Gastroenterology. 1985 Aug;89(2):279-86
pubmed: 4007419
Dig Liver Dis. 2015 Jun;47(6):518-22
pubmed: 25861840
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Cancer Treat Rev. 2011 May;37(3):212-20
pubmed: 20724077
Ann Hepatol. 2021 May-Jun;22:100278
pubmed: 33129978
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Eur J Gastroenterol Hepatol. 2018 Jan;30(1):44-53
pubmed: 29076939
Dig Liver Dis. 2016 Jul;48(7):798-805
pubmed: 27263056
Major Probl Clin Surg. 1964;1:1-85
pubmed: 4950264
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
pubmed: 15761078
J Gastrointest Oncol. 2013 Mar;4(1):45-52
pubmed: 23450240
Br J Surg. 1999 Feb;86(2):176-80
pubmed: 10100782
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Hepatology. 2011 May;53(5):1580-9
pubmed: 21351114
J Hepatol. 2003;38 Suppl 1:S136-49
pubmed: 12591191
Cancer. 2008 Jan 15;112(2):352-61
pubmed: 18008352
Cancers (Basel). 2020 Mar 26;12(4):
pubmed: 32224882
Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
pubmed: 15508102
Int J Cancer. 2001 Oct 15;94(2):153-6
pubmed: 11668491
J Vasc Interv Radiol. 2013 Apr;24(4):509-17
pubmed: 23428355
Cancers (Basel). 2020 Jul 15;12(7):
pubmed: 32679897
J Hepatol. 2014 Dec;61(6):1287-96
pubmed: 25016222
Cancers (Basel). 2021 Feb 15;13(4):
pubmed: 33672012
Hepatology. 1998 Sep;28(3):751-5
pubmed: 9731568
J Hepatol. 1995 Apr;22(4):410-5
pubmed: 7665860